- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07795164
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (PERFORMA)
A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Shaheen Tomah, MD
- Numero di telefono: 240-235-0145
- Email: performa@altimmune.com
Luoghi di studio
-
-
Puerto Rico
-
San Juan, Puerto Rico, Porto Rico, 00927
- Reclutamento
- Altimmune Clinical Study Site
-
-
-
-
Alabama
-
Dothan, Alabama, Stati Uniti, 36301
- Reclutamento
- Altimmune Clinical Study Site
-
-
Arizona
-
Chandler, Arizona, Stati Uniti, 85224
- Reclutamento
- Altimmune Clinical Study Site
-
Tucson, Arizona, Stati Uniti, 85712
- Reclutamento
- Altimmune Clinical Study Site
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- Reclutamento
- Altimmune Clinical Study Site
-
North Little Rock, Arkansas, Stati Uniti, 72117
- Reclutamento
- Altimmune Clinical Study Site
-
-
California
-
Fountain Valley, California, Stati Uniti, 92708
- Reclutamento
- Altimmune Clinical Study Site
-
Fresno, California, Stati Uniti, 93720
- Reclutamento
- Altimmune Clinical Study Site
-
Gardena, California, Stati Uniti, 90247
- Reclutamento
- Altimmune Clinical Study Site
-
Huntington Park, California, Stati Uniti, 90255
- Reclutamento
- Altimmune Clinical Study Site
-
La Mesa, California, Stati Uniti, 91942
- Reclutamento
- Altimmune Clinical Study Site
-
Long Beach, California, Stati Uniti, 90815
- Reclutamento
- Altimmune Clinical Study Site
-
Orange, California, Stati Uniti, 92866
- Reclutamento
- Altimmune Clinical Study Site
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- Altimmune Clinical Study Site
-
Poway, California, Stati Uniti, 92064
- Reclutamento
- Altimmune Clinical Study Site
-
Van Nuys, California, Stati Uniti, 91405
- Reclutamento
- Altimmune Clinical Study Site
-
-
Colorado
-
Englewood, Colorado, Stati Uniti, 80113
- Reclutamento
- Altimmune Clinical Study Site
-
-
Florida
-
Boca Raton, Florida, Stati Uniti, 33434
- Reclutamento
- Altimmune Clinical Study Site
-
Bradenton, Florida, Stati Uniti, 34209
- Reclutamento
- Altimmune Clinical Study Site
-
Miami, Florida, Stati Uniti, 33173
- Reclutamento
- Altimmune Clinical Study Site
-
Miami, Florida, Stati Uniti, 33122
- Reclutamento
- Altimmune Clinical Study Site
-
Miami Lakes, Florida, Stati Uniti, 33016
- Reclutamento
- Altimmune Clinical Study Site
-
Ocala, Florida, Stati Uniti, 34471
- Reclutamento
- Altimmune Clinical Study Site
-
Orlando, Florida, Stati Uniti, 32803
- Reclutamento
- Altimmune Clinical Study Site
-
Port Orange, Florida, Stati Uniti, 32127
- Reclutamento
- Altimmune Clinical Study Site
-
-
Georgia
-
Dalton, Georgia, Stati Uniti, 30720
- Reclutamento
- Altimmune Clinical Study Site
-
-
Indiana
-
South Bend, Indiana, Stati Uniti, 46635
- Reclutamento
- Altimmune Clinical Study Site
-
-
Louisiana
-
Bastrop, Louisiana, Stati Uniti, 71220
- Reclutamento
- Altimmune Clinical Study Site
-
Marrero, Louisiana, Stati Uniti, 70072
- Reclutamento
- Altimmune Clinical Study Site
-
Monroe, Louisiana, Stati Uniti, 71201
- Reclutamento
- Altimmune Clinical Study Site
-
-
Maryland
-
Laurel, Maryland, Stati Uniti, 20708
- Reclutamento
- Altimmune Clinical Study Site
-
-
Massachusetts
-
New Bedford, Massachusetts, Stati Uniti, 02740
- Reclutamento
- Altimmune Clinical Study Site
-
-
Missouri
-
Columbia, Missouri, Stati Uniti, 65201
- Reclutamento
- Altimmune Clinical Study Site
-
Kansas City, Missouri, Stati Uniti, 64131
- Reclutamento
- Altimmune Clinical Study Site
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87107
- Reclutamento
- Altimmune Clinical Study Site
-
-
North Carolina
-
Fayetteville, North Carolina, Stati Uniti, 28304
- Reclutamento
- Altimmune Clinical Study Site
-
-
Ohio
-
Brooklyn, Ohio, Stati Uniti, 44144
- Reclutamento
- Altimmune Clinical Study Site
-
Springboro, Ohio, Stati Uniti, 45066
- Reclutamento
- Altimmune Clinical Study Site
-
Westlake, Ohio, Stati Uniti, 44145
- Reclutamento
- Altimmune Clinical Study Site
-
-
Rhode Island
-
East Greenwich, Rhode Island, Stati Uniti, 02818
- Reclutamento
- Altimmune Clinical Study Site
-
-
Texas
-
Austin, Texas, Stati Uniti, 78757
- Reclutamento
- Altimmune Clinical Study Site
-
Bellaire, Texas, Stati Uniti, 77401
- Reclutamento
- Altimmune Clinical Study Site
-
Brownsville, Texas, Stati Uniti, 78520
- Reclutamento
- Altimmune Clinical Study Site
-
Corpus Christi, Texas, Stati Uniti, 78404
- Reclutamento
- Altimmune Clinical Study Site
-
Dallas, Texas, Stati Uniti, 75230
- Reclutamento
- Altimmune Clinical Study Site
-
Edinburg, Texas, Stati Uniti, 78539
- Reclutamento
- Altimmune Clinical Study Site
-
Farmers Branch, Texas, Stati Uniti, 75234
- Reclutamento
- Altimmune Clinical Study Site
-
Forney, Texas, Stati Uniti, 75126
- Reclutamento
- Altimmune Clinical Study Site
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- Altimmune Clinical Study Site
-
Georgetown, Texas, Stati Uniti, 78626
- Reclutamento
- Altimmune Clinical Study Site
-
Houston, Texas, Stati Uniti, 77004
- Reclutamento
- Altimmune Clinical Study Site
-
Houston, Texas, Stati Uniti, 77079
- Reclutamento
- Altimmune Clinical Study Site
-
Kingwood, Texas, Stati Uniti, 77339
- Reclutamento
- Altimmune Clinical Study Site
-
Pasadena, Texas, Stati Uniti, 77505
- Reclutamento
- Altimmune Clinical Study Site
-
San Antonio, Texas, Stati Uniti, 78215
- Reclutamento
- Altimmune Clinical Study Site
-
San Antonio, Texas, Stati Uniti, 78209
- Reclutamento
- Altimmune Clinical Study Site
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- Altimmune Clinical Study Site
-
Sugar Land, Texas, Stati Uniti, 77479
- Reclutamento
- Altimmune Clinical Study Site
-
Waco, Texas, Stati Uniti, 76710
- Reclutamento
- Altimmune Clinical Study Site
-
-
Utah
-
Ogden, Utah, Stati Uniti, 84405
- Reclutamento
- Altimmune Clinical Study Site
-
West Jordan, Utah, Stati Uniti, 84088
- Reclutamento
- Altimmune Clinical Study Site
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- Reclutamento
- Altimmune Clinical Study Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
All subjects:
- No significant changes in body weight (±5%) and not participating in a structured weight loss program for the 3 months prior to screening (or since the historical biopsy, if applicable)
- Body mass index (BMI) ≥ 25.0 kg/m2; if Asian, BMI ≥ 23.0 kg/m2
- Type 2 diabetes (T2D) or at least 2 components of metabolic syndrome
- Subject agrees to have liver biopsy(ies) as required per protocol
Cohort 1 - Histologic diagnosis of F2/F3 MASH based on liver biopsy during screening or historical biopsy within 6 months before screening
Cohort 2 - Presumed F2/F3 MASH based on noninvasive testing
Exclusion Criteria:
- Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic liver disease other than MASH; liver function tests (ALT, AST; alkaline phosphatase; total bilirubin; INR; and platelet count) outside of acceptable ranges; positive HBsAg; active hepatitis C
- Uncontrolled T2D or clinically significant persistent hyperglycemia
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore placebo: Placebo
|
Placebo SC Injection |
|
Sperimentale: Pemvidutide 2,4 mg
|
Pemvidutide SC Injection |
|
Sperimentale: Pemvidutide 1.8 mg
|
Pemvidutide SC Injection |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Clinical Outcome Event
Lasso di tempo: Baseline through end of study (approximately Month 60)
|
Time to first occurrence of any of the following events through the end of the study: Histologic progression to cirrhosis (F4) on liver biopsy; Liver related events; Liver transplantation; or Death due to any cause |
Baseline through end of study (approximately Month 60)
|
|
Histological Response: MASH resolution
Lasso di tempo: Baseline through Week 52
|
Proportion of subjects achieving MASH resolution (according to NASH Clinical Research Network [CRN] classification) without worsening of fibrosis |
Baseline through Week 52
|
|
Histological Response: Fibrosis improvement
Lasso di tempo: Baseline through Week 52
|
Proportion of subjects achieving ≥ 1 stage improvement in liver fibrosis according to the NASH CRN fibrosis staging system without worsening of MASH |
Baseline through Week 52
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Histologic Response: Proportion of subjects achieving both MASH resolution (according to NASH CRN classification) without worsening of fibrosis and ≥ 1 stage improvement in liver fibrosis without worsening of MASH
Lasso di tempo: Baseline through Week 52
|
Baseline through Week 52
|
|
HistoIndex qFibrosis: Proportion of subjects with at least a 1 stage improvement in qFibrosis
Lasso di tempo: Baseline through Week 52
|
Baseline through Week 52
|
|
Anthropometric parameters: Relative (%) change from baseline in body weight (kg)
Lasso di tempo: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in body mass index (BMI; kg/m2)
Lasso di tempo: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in waist circumference (cm)
Lasso di tempo: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in alanine aminotransferase (ALT; U/L)
Lasso di tempo: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in enhanced liver fibrosis (ELF) score
Lasso di tempo: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Relative (%) change from baseline in vibration controlled transient elastography (VCTE; kPa) by Fibroscan
Lasso di tempo: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in core symptoms of MASH on the NASH-CHECK questionnaire.
Lasso di tempo: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Short-form 36 (SF-36) summary scores.
Lasso di tempo: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) domain scores.
Lasso di tempo: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- ALT-801-301
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .